Three from MIT receive National Health Institute Awards
Michael Birnbaum, Anders Hansen, and Tami Lieberman receive NIH Director’s New Innovator Awards from the NIH Common Fund’s High-Risk, High-Reward Research program.
Download RSS feed: News Articles / In the Media / Audio
Michael Birnbaum, Anders Hansen, and Tami Lieberman receive NIH Director’s New Innovator Awards from the NIH Common Fund’s High-Risk, High-Reward Research program.
InfiniteMD virtually connects patients with leading medical specialists to give advice on treatment plans, diagnoses, and more.
The company Health at Scale uses machine learning to improve outcomes for individual patients.
The startup Kinsa uses its smart thermometers to detect and track the spread of contagious illness before patients go to the hospital.
MIT researchers propose a design to overcome a major challenge in hydrocephalus catheters — clogging — by leveraging catheter geometry.
Specialized nanoparticles create a “breath signal” that could be used to diagnose pneumonia and other infectious or genetic diseases.
Award recognizes scholars who pursue graduate studies focusing on “bold, risk-taking research.”
Technique paves the way for more energy efficient, 3D microprocessors.
Multi-institutional MassCPR initiative announces more than $16.5 million to support 62 Boston-area projects.
Suggested design could make it easier to divide air flow for Covid-19 patients in emergencies when no other options are available.
Faculty members Abhijit Banerjee, Bonnie Berger, and Roger Summons elected by peers for outstanding contributions to research.
Students around the country recognized for innovative solutions to better single-use plastic, spacecraft and aircraft fuel gauges, surgery techniques, and more.
Inaugural AI Powered Drug Discovery and Manufacturing Conference drew pharmaceutical companies, government regulators, and pioneering drug researchers.
Professor of chemistry and IMES core member is recognized for his leadership and pioneering spirit.
The Audacious Project commitment will support the development of new classes of antibiotics to treat the world’s deadliest bacterial pathogens.